OTO-313 in Subjects With Subjective Tinnitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

May 29, 2020

Study Completion Date

May 29, 2020

Conditions
Tinnitus, Subjective
Interventions
DRUG

OTO-313

single intratympanic injection of gacyclidine

DRUG

Placebo

single intratympanic injection of placebo

Trial Locations (16)

10605

Northwell Health at ENT and Allergy Associates, White Plains

10882

Summit Medical Group, Berkeley Heights

11042

Northwell Health, Hearing & Speech Center, New Hyde Park

14226

Dent Neurosciences Research Center, Amherst

26506

WVU Medicine, Morgantown

27103

Piedmont Ear, Nose, and Throat Associates, Winston-Salem

28210

Charlotte Eye Ear Nose & Throat Associates, Charlotte

34239

Silverstein Institute/Ear Research Foundation, Sarasota

40207

Advanced ENT and Allergy, Louisville

60657

ChicagoENT, Chicago

70072

Tandem Clinical Research, LLC, Marrero

78217

Worldwide Clinical Trials, San Antonio

80909

Colorado ENT and Allergy, Colorado Springs

84790

Chrysalis Clinical Research, St. George

90057

House Clinic, Los Angeles

92121

California Head & Neck Specialists, San Diego

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Otonomy, Inc.

INDUSTRY